• Mikaela Coleman

WHO urges oral treatment regimens for drug-resistant TB

Updated: Jun 17, 2020

This week the WHO has updated their guidelines, recommending shorter and fully oral treatment regimens for patients with MDR-TB

The updated regimens will allow MDR-TB patients to undergo treatment in the safety of their own homes, and in a shorter time-frame. This update is especially relevant at this time when the COVID-19 pandemic makes attending clinics for treatment a precarious concept for many patients. The WHO is hopeful that the guideline update will improve regimen adherence and treatment outcomes for patients.

The new regimen is 6-9 months long as opposed to the previous regimens which could be up to 18-20 months in duration. The new regimen incorporates a previously unused drug -- pretomanid -- to be used in combination with bedaquiline and linezolid. This regimen is recommended for operational research in MDR-TB patients with additional fluroquinolone resistance.

Further updates to the guidelines include information on the safety of bedaquiline for treatment duration greater than 6 months, and for use during pregnancy.

To read more about the guideline updates, access the WHO report here.

17 views0 comments

Recent Posts

See All

To get in touch with us, 

please email our executive officer at


  • LinkedIn
  • Facebook
  • Twitter

©2023 by TB CRE. Proudly created with wix.com